ClinicalTrials.gg
Active, not recruitingNCT04554602ENDOFUSIONUpdated Jan 25, 2024

Fusion Ultrasound for Diagnosis and Monitoring of Endometriosis Lesions

An observational study in Endometriosis, sponsored by Assistance Publique - Hôpitaux de Paris. Active, not recruiting at 1 site in France. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
24
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Endometriosis by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, none of them phase 3. Endometriosis · Assistance Publique - Hôpitaux de Paris.

Started
2021
the only one that year
Observational
6 of 12
3 open now
Registered
7th of 12
by date

Among the 12 studies in Endometriosis by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2021, is one of 6 observational ones, and was the 7th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

6 of the 12 studies in Endometriosis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Endometriosis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The aim of the study is evaluate the fusion ultrasound performance compared to MRI and coelioscopy diagnosis when a surgical intervention is performed.

Read the detailed description

The research is about diagnosis performance between fusion ultrasound and the gold standard (MRI coelioscopy ). Fusion ultrasound is a no-invasive scientific technical which allow with security to evaluate the progress of endometriosis lesions. During 39 months, 200 patients will be follow. In one arm, there is the control group with women without endometriosis. In the second arm, there is the patient with endometriosis. We will compare monitoring differences between gold standard and fusion ultrasound ( Cost assessment,exams duration, reproductibility, the link between symptoms and evolution of the lesion size).

03

Conditions studied

  • Endometriosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any major patient with an indication for pelvic MRI and pelvic ultrasound outside a proven cancer indication (suspicion of endometriosis or other pathology for the control population).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients from 18 to 50 years old
  • Patient informed and who gave her non-opposition to participate in the research
  • Patient with an indication for pelvic MRI and pelvic ultrasound either for the exploration of endometriosis or pelvic pain, or for another gynaecological pathology (ovarian cyst, poly-myomatous uterus, uterine malformation) outside of a proven cancer indication.
  • Patient affiliated to a social security or entitled to a social security allowance

Exclusion criteria

Exclusion Criteria:

  • Patient with a proven cancerous pathology at the time of the prescription of the complementary examinations.
  • Virgin patient
  • Pregnant patient
  • Patients under protective measures
  • to MRI (claustrophobia, intracorporeal metallic foreign body)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
24 participants (actual)
Patient registry
No

Groups and cohorts

  • Patient with endometriosis or suspicion of endometriosis

    * Information and collection of the non-objection before inclusion * Interrogation, clinical examination, EHP30 and SF36 form at inclusion * MRI, pelvic ultrasound (coupled with fusion ultrasound) * Laparoscopy if indicated after MRI, ultrasound and fusion ultrasound * Monitoring by form and fusion ultrasound at 6 months and then once a year for 3 years

    Diagnostic Test: Fusion ultrasound

  • Patient with other gynaecological pathology

    * Information and collection of the non-opposition before inclusion * Interrogation, clinical examination, EHP30 and SF36 form at inclusion * MRI, pelvic ultrasound (coupled with fusion ultrasound) * laparoscopy if indicated after MRI, ultrasound and fusion ultrasound

    Diagnostic Test: Fusion ultrasound

Interventions

  • Diagnostic testFusion ultrasound

    Fusion ultrasound is a technique that allows a volume acquired in MRI to be coupled to an ultrasound scan with real-time image synchronisation.

06

What researchers measure

Primary outcomes

  1. Sensitivity, specificity, positive predictive value (VPP) and negative predictive value (VPN) of fusion ultrasound compared to transvaginal ultrasound and MRI for the diagnosis of endometriosis lesions

    To evaluate the diagnostic performance of fusion ultrasound compared to transvaginal gynaecological ultrasound and MRI for the diagnosis of endometriosis lesions.

    Time frame: 3 years and 3 months

Secondary outcomes

  1. Evaluate the reproducibility of the conclusions of the fusion ultrasound between 2 operators.

    Evaluation of the reproducibility by an intra-class correlation test for the conclusions of fusion ultrasound between two operators.

    Time frame: 3 years and 3 months

  2. To evaluate the contribution of fusion ultrasound in the follow-up of patients suffering from endometriosis, in particular with an ultrasound follow-up in comparison with an initial reference MRI in the case of medical or surgical management.

    Correlation between the evolution of clinical and quality of life symptoms (EHP30 form and Short Form 36) and the evolution of lesion size between initial MRI and follow-up ultrasounds at 6 months and one year

    Time frame: 3 years and 3 months

  3. Compare the duration of a standard ultrasound scan to an ultrasound scan with fusion

    Comparison of the average examination time by a Student T-test between standard and fusion ultrasound.

    Time frame: 3 years and 3 months

  4. Evaluation of the cost of imaging for 3 years between an annual fusion ultrasound surveillance in replacement of a annual MRI surveillance

    Comparison of imaging costs will be carried out over 3 years between a conventional procedure with annual MRI and the procedure being evaluated

    Time frame: 3 years and 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Dec 2026, 69 months after the start.

Of 158 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 69 months is above that.

Counting every sponsor, half of 185 studies reached it within 30 months; a quarter within 14 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2020
First posted
Sep 18, 2020
StartActual
Mar 1, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04554602
Responsible party
Sponsor
First posted
Sep 18, 2020
Start date
Mar 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 25, 2024

Study contacts

Perrine CAPMAS, DR
principal investigator · APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion